Samsung Affiliates Aim For IPO, Biologics Expansion
This article was originally published in PharmAsia News
Samsung Group's two biopharma affiliates are aiming high to become global leaders in the development of biosimilars and production of biomedicines. Although the largest South Korean conglomerate is a late starter compared to other biosimilar rivals including Celltrion, its affiliates Samsung Bioepis and Samsung Biologics have been making rapid progress on the back of strong group-wide support.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.